RhBMP-7 for the treatment of nonunion of fractures of long bones

Bone Joint J. 2015 Jul;97-B(7):997-1003. doi: 10.1302/0301-620X.97B7.35089.

Abstract

We report the outcome of 84 nonunions involving long bones which were treated with rhBMP-7, in 84 patients (60 men: 24 women) with a mean age 46 years (18 to 81) between 2003 and 2011. The patients had undergone a mean of three previous operations (one to 11) for nonunion which had been present for a mean of 17 months (4 months to 20 years). The nonunions involved the lower limb in 71 patients and the remainder involved the upper limb. A total of 30 nonunions were septic. Treatment was considered successful when the nonunion healed without additional procedures. The relationship between successful union and the time to union was investigated and various factors including age and gender, the nature of the nonunion (location, size, type, chronicity, previous procedures, infection, the condition of the soft tissues) and type of index procedure (revision of fixation, type of graft, amount of rhBMP-7) were analysed. The improvement of the patients' quality of life was estimated using the Short Form (SF) 12 score. A total of 68 nonunions (80.9%) healed with no need for further procedures at a mean of 5.4 months (3 to 10) post-operatively. Multivariate logistic regression analysis of the factors affecting union suggested that only infection significantly affected the rate of union (p = 0.004).Time to union was only affected by the number of previous failed procedures (p = 0.006). An improvement of 79% and 32.2% in SF-12 physical and mental score, respectively, was noted within the first post-operative year. Rh-BMP-7 combined with bone grafts, enabled healing of the nonunion and improved quality of life in about 80% of patients. Aseptic nonunions were much more likely to unite than septic ones. The number of previous failed operations significantly delayed the time to union.

Keywords: Bone Morphogenetic Protein 7; bone grafts; consolidation; infection; nonunion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Morphogenetic Protein 7 / therapeutic use*
  • Bone Transplantation*
  • Combined Modality Therapy
  • Female
  • Fractures, Bone / drug therapy*
  • Fractures, Bone / surgery*
  • Fractures, Ununited / drug therapy*
  • Fractures, Ununited / surgery*
  • Humans
  • Male
  • Middle Aged
  • Young Adult

Substances

  • BMP7 protein, human
  • Bone Morphogenetic Protein 7